STK shares are up about 3% since the medical device company reported 4th-quarter and 2012 results Jan. 24. Stryker said yesteday that it plans to issue a 26.5¢ dividend to shareholders.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
MASSDEVICE ON CALL — Safety concerns by the FDA have stalled the development of an artificial pancreas to treat Type I diabetes.
Advocates of the artificial pancreas have been calling for the federal watchdog agency to issue a clear guidance for months and they could get an answer as early as this afternoon.
MASSDEVICE ON CALL — Men and women with implanted defibrillators may experience sexual performance problems related to a fear of getting shocked during sex, according to the American Heart Assn.
In a survey of more than 150 people, average sexual function scores among men with ICDs were consistent with mild erectile dysfunction while those without the implants were in normal range.
Women’s average scores were similar among those with ICD and those without, but women reporting high level of anxiety had lower sexual function scores.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
The Juvenile Diabetes Research Foundation unveiled a petition today, signed by more than 100,000 senators, doctors and patients, urging the FDA to issue swift and clear guidance for the development of an artificial pancreas for diabetics.
The petition, which was posted on the JDRF’s website Oct. 3, calls for the federal watchdog agency to issue a guidance that speeds up its recommended device development restrictions, allowing short-term, in-hospital evaluations of artificial pancreas systems and followed by outpatient trials of no more than three months long.
MASSDEVICE ON CALL — Teenaged delegates from the Juvenile Diabetes Research Foundation testified on Capitol Hill, urging Congress to accelerate research and review of artificial pancreas systems for managing insulin for patients with type 1 diabetes.